Personalis 2025 Q2 Earnings Sustained Losses Despite Sequential Clinical Growth

Personalis reported Q2 2025 earnings on August 5, 2025, showing a 23.8% year-over-year decline in revenue to $17.20 million. The company narrowed its per-share loss to $0.23 from $0.24, but net losses widened to $20.06 million compared to $12.80 million in the prior year. This marks the ninth consecutive year of losses for the firm. Personalis revised its 2025 revenue guidance to $70–$80 million from the previous $80–$90 million range, citing biopharma project delays and uncertainty around reimbursement timelines.

Revenue
Pharma tests and services accounted for the largest revenue portion at $11.02 million, followed by population sequencing at $3.31 million and enterprise sales at $2.31 million. The clinical diagnostics segment contributed $469,000, while other revenue totaled $88,000.

Earnings/Net Income
Despite a slight improvement in per-share loss, the company’s net loss expanded by 56.7% year-over-year. The ongoing losses reflect structural challenges, with no sign of profitability in sight.

Price Action
The stock edged down 0.88% on the latest trading day but gained 1.08% for the week. However, it fell sharply by 24.30% month-to-date.

Post Earnings Price Action Review
A strategy of buying PSNL shares after a revenue increase in the earnings report and holding for 30 days delivered an 81.12% return over three years, outperforming the 48.58% benchmark. The strategy exhibited a 22.76% CAGR with no maximum drawdown, indicating strong performance and risk control.

CEO Commentary
CEO Christopher M. Hall highlighted a 59% sequential rise in clinical test volume to nearly 3,500 results, and a physician base now exceeding 600. He noted progress with the Tempus partnership and confidence in Medicare coverage for two indications by year-end. Hall outlined a three-point plan to achieve the new revenue guidance, emphasizing leverage on key growth drivers.

Guidance
The company expects Q3 2025 revenue of $12–$14 million, with biopharma revenue at $11–$13 million and clinical revenue between $3–$6 million. It also anticipates Medicare reimbursement to drive NeXT Personal growth post-coverage and forecasts a gross margin of 22%–24% for 2025.

Additional News
On August 6, 2025, Personalis reaffirmed its updated 2025 revenue guidance of $70–$80 million, down from $80–$90 million. Management emphasized strong execution of its MRD strategy, with clinical adoption of NeXT Personal accelerating sharply, as test volume rose 59% sequentially. CEO Christopher Hall noted the company is on track to secure Medicare coverage for two indications by year-end, a key catalyst for future growth. The statement underscored continued focus on commercial partnerships, including Tempus, across four cancer indications.